Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

Neural Portfolio Company Hanf.com Expands German Retail Footprint with New Muhldorf am Inn Store and Four Refurbished Locations

Neural Therapeutics Retail Expansion Confirms Growth Trajectory Ahead of Critical M&A Vote

By The Northwire Desk — AI Analysis May 19, 2026 · 07:31 NURL · 0.015 Neural Therapeutics Inc.
Executive Summary
  • Operational Update: Portfolio company CWE European Holdings Inc. (Hanf.com) opened a new retail store in Muhldorf am Inn, Germany.
  • Refurbishments: Four existing locations (Straubing, Regensburg, Herford, Freising) have been refurbished to improve customer experience and brand visibility.
  • Strategic Context: Neural Therapeutics holds 30.75% ownership in CWE with an option to acquire the remaining 69.25%. This expansion supports the scaling of the German retail footprint prior to the proposed full acquisition (Series B Transactions).
  • Meeting Schedule: Shareholder meeting for approval of Series B Transactions and name change is scheduled for May 25, 2026.
Material Impact
  • Incremental Growth: The store opening confirms execution of the expansion strategy announced in November 2025 and February 2026. It validates management's claim that smaller towns offer efficient market penetration opportunities.
  • No Surprise Factor: This operational update was anticipated given the aggressive retail acquisition history (Bielefeld/Herford in Nov 2025) and the stated goal of scaling to support the full acquisition valuation.
  • Margin Concerns Persist: While revenue growth is positive, historical data indicates a significant compression in gross margins from ~58% (FY24) to ~35% (FY25 Preliminary). This news does not address the profitability quality issue; it focuses on top-line expansion via wholesale and retail mix.
  • M&A Dependency: The material value driver remains the approval of the Series B Transactions (full acquisition) on May 25, 2026. This release is a supporting narrative for that vote rather than a standalone valuation catalyst.
NURL · Price
Company Overview
  • Company: Neural Therapeutics Inc., transitioning to Hanf.com Inc. upon completion of Series B Transactions.
  • Flagship Project: CWE European Holdings Inc. (Hanf.com), Germany's leading CBD retailer.
  • Development Status: Operating 21+ retail locations in Germany, expanding via acquisition and refurbishment. Moving from pure R&D to commercial operations through full integration of Hanf.com.
  • Revenue Trajectory: FY2024 Revenue $7.1M (65% growth). FY2025 Preliminary Revenue $11.2M (58% growth).
  • Profitability: FY2024 Net Income positive ($371K). FY2025 Preliminary shows normalized operating income but reported net loss due to non-recurring fees (~$600K).
Read the original news release →

More from Neural Therapeutics Inc.

Jun 12, 2026 · 07:31

Neural Therapeutics Announces AGSM Results, CFO Appointment and Welcomes Positive Developments in the German Cannabis Market

M&A / Property May 01, 2026 · 08:04

Neural Therapeutics Confirms Shareholder Vote for Hanf.com Acquisition Amidst Revenue Growth and Margin Compression

M&A / Property Mar 27, 2026 · 07:32

Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant

Financings Feb 19, 2026 · 08:54

Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing

Technical Study Feb 10, 2026 · 07:31

Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income

Earnings Jan 27, 2026 · 10:01

Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products

Other